Axonal and neuronal pathology in multiple sclerosis: What have we learnt from animal models

Experimental Neurology

Volumn 225, Issue 1, 2010, Pages 2-8

  Lassmann, Hans ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Axons; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neurodegeneration; Neuroprotection

Indexed keywords

AUTOANTIBODY; BETA INTERFERON; CALPAIN; ERYTHROPOIETIN; GLATIRAMER; ION CHANNEL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHYLPREDNISOLONE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL BLOCKING AGENT; T LYMPHOCYTE ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AXONAL INJURY; CELL SPECIFICITY; DEMYELINATING DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GRAY MATTER; HUMAN; MACROPHAGE ACTIVATION; MICROGLIA; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHYSICAL DISABILITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; WHITE MATTER; ANIMAL; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGY; METABOLISM; NERVE CELL; NERVE DEGENERATION; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AXONS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEURONS;

EID: 77955656367     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.10.009     Document Type: Review

References (71)

1. Aboul-Enein F., Rauschka H., Kornel B., Stadelmann C., Stefferl A., Brück W., Lucchinetti C.F., Schmidbauer M., Jellinger K., Lassmann H. Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropath. Exp. Neurol. 2003, 62:25-33.
2. Aboul-Enein F., Weiser P., Höftberger R., Lassmann H., Bradl M. Transient axonal injury in the absence of demyelination: a correlate of clinical disease in acute experimental autoimmune encephalomyelitis. Acta Neuropathol. (Berl) 2006, 111:539-547.
3. Abramov A.Y., Duchen M.R. Impaired mitochondrial bioenergetics determines glutamate-induced delayed calcium deregulation in neurons. Biochem. Biophys. Acta 2009, Epub ahead of print.
4. Aranami T., Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Intern. 2008, 57:115-120.
5. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
6. Bechtold D.A., Miller S.J., Dawson A.C., Sun Y., Kapoor R., Berry D., Smith K.J. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol. 2006, 253:1542-1551.
7. Ben Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981, 11:195-199.
8. Bjartmar C., Kidd G., Mork S., Rudick R., Trapp B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000, 48:893-901.
9. Black J.A., Liu S., Hains B.C., Saab C.Y., Waxman S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006, 129:3147-3149.
10. Black J.A., Liu S., Carrithers M., Carrithers L.M., Waxman S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 2007, 62:21-33.
11. Bo L., Vedeler C.A., Nyland H.I., Trapp B.D., Mork S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropath. Exp. Neurol. 2003, 62:723-732.
12. Boretius S., Gadjanski I., Demmer I., Bähr M., Diem R., Michaelis T., Frahm J. MRI of optic neuritis in a rat model. Neuroimage 2008, 41:323-334.
13. Brink B.P., Veerhuis R., Breij E.C., van der Valk P., Dijkstra C.D., Bo L. The pathology of multiple sclerosis is location dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropath. Exp. Neurol. 2005, 64:147-155.
14. Cifelli A., Arridge M., Jezzard P., Esiri M.M., Palace J., Matthews P.M. Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 2002, 52:650-653.
15. DeLuca G.C., Williams K., Evangelou N., Ebers G.C., Esiri M.M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006, 129:1507-1516.
16. Diem R., Hobom M., Maier K., Weisert R., Storch M.K., Meyer R., Bähr M. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogeneous nueroprotective pathway. J. Neurosci. 2003, 23:6993-7000.
17. Diem R., Sättler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., Bähr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005, 128:375-385.
18. Diem R., Sättler M.B., Bähr M. Neurodegeneration and -protection in autoimmune CNS inflammation. J. Neuroimmunol. 2007, 184:27-36.
19. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59:478-489.
20. Evangelou N., Konz D., Esiri M.M., Smith S., Palace J., Matthews P.M. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000, 123:1845-1849.
21. Evangelou N., Konz D., Esiri M.M., Smith S., Palace J., Matthews P.M. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001, 124:1813-1820.
22. Evangelou N., DeLuca G.C., Owens T., Esiri M.M. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 2005, 128:29-34.
23. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
24. Friese M.A., Craner M.J., Etzensperger R., Vergo S., Wemmie J.A., Welsh M.J., Vincent A., Fugger L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med. 2007, 13:1483-1489.
25. Frischer J.M., Bramow S., Dal Bianco A., Lucchinetti C., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis. Brain 2009, 132:1175-1189.
26. Gadjanski I., Boretius S., Williams S.K., Lingor P., Knöferle J., Sättler M.B., Fairless R., Hochmeister S., Sühs K.W., Michaelis T., Frahm J., Storch M.K., Bähr M., Diem R. Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis. Ann. Neurol. 2009, 66:81-93.
27. Gilmore C.P., Deluca G.C., Bö L., Owens T., Lowe J., Esiri M.M., Evangelou N. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol. 2009, 19:642-649.
28. Hampton D.W., Anderson J., Pryce G., Irvine K.A., Giovannoni G., Fawcett J.W., Compston A., Franklin R.J., Baker D., Chandran S. An experimental lodel of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J. Neuroimmunol. 2008, 201-202:200-211.
29. Howe C.L., Adelson J.D., Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiol. Dis. 2007, 25:354-359.
30. Huzinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis. 2008, 32:461-470.
31. Kerlero de Rosbo N., Mendel I., Ben Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG) derived peptide: preliminary analysis of MOG T-cell epitopes. Eur. J. Immunol. 1995, 25:985-993.
32. Kornek B., Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol. 1999, 9:651-656.
33. Kornek B., Storch M., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Amer. J. Pathol. 2000, 157:267-276.
34. Kornek B., Storch M.K., Bauer J., Djamshidian A., Weissert R., Wallstrom E., Stefferl A., Zimprich F., Olsson T., Linington C., Schmidbauer M., Lassmann H. Distribution of calcium channel subunit in dystrophic axons in multiple sclerosis and experiemntal autoimmune encephalomyelitis. Brain 2001, 124:1114-1124.
35. Krishnamoorthy G., Saxena A., Mars L.T., Domingues H.S., Mentele R., Ben Nun A., Lassmann H., Dornmair K., Kurschus F.C., Liblau R.S., Wekerle H. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 2009, 15:626-632.
36. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125:2202-2212.
37. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
38. Kutzelnigg A., Faber-Rod J.C., Bauer J., Lucchinetti C.F., Sorensen P.S., Laursen H., Stadelmann C., Brück W., Rauschka H., Schmidbauer M., Lassmann H. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007, 17:38-44.
39. Lassmann H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Schriftenr. Neurol. 1983, 25:1-135.
40. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 1988, 130:443-454.
41. Lo A.C., Black J.A., Waxman S.G. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 2002, 28:1909-1912.
42. Mahad D.J., Ziabreva I., Lassmann H., Turnbull D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 2008, 131:1722-1735.
43. Mahad D.J., Lassmann H., Turnbull D.M. Review: Mitochondria and disease progression in multiple sclerosis. Neuropath. Appl. Neurobiol. 2008, 34:577-589.
44. Mahad D.J., Ziabreva I., Campbell G., Lax N., White K., Hanson P.S., Lassmann H., Turnbull D.M. Mitochondrial changes within in multiple sclerosis. Brain 2009, 132:1161-1174.
45. Maier K., Kuhnert A.V., Taheri N., Sättler M.B., Storch M.K., Williams S.K., Bähr M., Diem R. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am. J. Pathol. 2006, 169:1353-1364.
46. Marburg O. Die sogenannte akute Multiple Sklerose. Jahrb. Psychiatrie 1906, 27:211-312.
47. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Wooley D.R., Al Hayani A., Davies S.N., Rasband M.N., Olsson T., Moldenhauer A., Velhin S., Hohlfeld R., Meinl E., Linington C. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007, 204:2363-2372.
48. Medana I.M., Gallimore A., Oxenius A., Martinic M.M., Wekerle H., Neumann H. MHC class I restricted killing of neurons by virus specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur. J. Immunol. 2000, 30:3623-3633.
49. Medana I., Martinic M.M.A., Wekerle H., Neumann H. Transection of MHC class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001, 159:809-815.
50. Mews I., Bergmann M., Bunkowski S., Gullotta F., Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult. Scler. 1998, 4:55-62.
51. Meyer R., Weissert R., Diem R., Storch M.K., de Graaf K.L., Kramer B., Bähr M. Acute neuronal apoptosis in a rat model of multiple sclerosis. J. Neurosci. 2001, 21:6214-6220.
52. Neumann H., Cavalie A., Jenne D.E., Wekerle H. Induction of MHC class I genes in neurons. Science 1995, 28:549-552.
53. Neumann H., Medana I., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trend Neurosci. 2002, 25:313-319.
54. Nitsch R., Pohl E.E., Smorodchenko A., Infante-Duarte C., Atkas O., Zipp F. Direct impact of T-cells in neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 2004, 24:2458-2464.
55. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50:389-400.
56. Pomeroy I.M., Matthews P.M., Frank J.A., Jordan E.K., Esiri M.M. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005, 128:2713-2721.
57. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997, 120:2149-2157.
58. Sättler M.B., Togni M., Gadjanski I., Sühs K.W., Meyer N., Bähr M., Diem R. Strain-specific susceptibiltity for neurodegeneration in a rat model of autoimmune optic neuritis. J. Neuroimmunol. 2008, 109:77-86.
59. Shintaku M., Hirano A., Llena J.F. Increased diameter of demyelinated axons in chronic multiple sclerosis of the spinal cord. Neuropathol. Appl. Neurobiol. 1998, 14:505-510.
60. Smith K.J. Axonal protection in multiple sclerosis-a particular need during remyelination?. Brain 2006, 129:3147-3149.
61. Smith K.J., Kapoor R., Hall S.M., Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 2001, 49:470-479.
62. Stadelmann C., Ludwin S., Tabira T., Guseo A., Lucchinetti C.F., Leel-Össy L., Ordinario A.T., Brück W., Lassmann H. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005, 128:979-987.
63. Storch M.K., Bauer J., Linington C., Olsson T., Weissert R., Lassmann H. Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J. Neuropathol. Exp. Neurol. 2006, 65:1137-1142.
64. Stys P.K. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 2005, 133:3-13.
65. Stys P.K., Jiang Q. Calpain-dependent neurofilament breakdown in anoxic and ischemic rat central axons. Neurosci. Lett. 2002, 328:150-154.
66. Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4:32-41.
67. Trapp B., Stys P. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8:80-291.
68. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
69. Tsunoda I., Tanaka T., Terry E.J., Fujinami R.S. Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: when can axonal injury be beneficial?. Am. J. Pathol. 2007, 170:214-226.
70. Vercellino M., Plano F., Votta B., Mutani R., Giordana M.T., Cavalla P. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2005, 64:1101-1107.
71. Wegner C., Esiri M.M., Chance S.A., Palace J., Matthews P.M. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006, 67:960-967.